Medpace Holdings, Inc. (MEDP) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Medpace Holdings, Inc. Do?
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio. Medpace Holdings, Inc. (MEDP) is classified as a large-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO August J. Troendle and employs approximately 5,200 people, headquartered in CINCINNATI, Ohio. With a market capitalization of $13.9B, MEDP is one of the prominent companies in the Industrials sector.
Medpace Holdings, Inc. (MEDP) Stock Rating — Hold (April 2026)
As of April 2026, Medpace Holdings, Inc. receives a Hold rating with a composite score of 44.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.MEDP ranks #741 out of 4,446 stocks in our coverage universe. Within the Industrials sector, Medpace Holdings, Inc. ranks #125 of 752 stocks, placing it in the top quartile of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MEDP Stock Price and 52-Week Range
Medpace Holdings, Inc. (MEDP) currently trades at $492.46. The stock lost $9.04 (1.8%) in the most recent trading session. The 52-week high for MEDP is $628.92, which means the stock is currently trading -21.7% from its annual peak. The 52-week low is $250.05, putting the stock 96.9% above its annual trough. Recent trading volume was 116K shares, suggesting relatively thin trading activity.
Is MEDP Overvalued or Undervalued? — Valuation Analysis
Medpace Holdings, Inc. (MEDP) carries a value factor score of 56/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 35.21x, compared to the Industrials sector average of 28.33x — a premium of 24%. The price-to-book ratio stands at 31.63x, versus the sector average of 2.23x. The price-to-sales ratio is 6.17x, compared to 0.50x for the average Industrials stock. On an enterprise value basis, MEDP trades at 29.40x EV/EBITDA, versus 5.70x for the sector. The EV/EBIT multiple is 23.02x.
Overall, MEDP's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Medpace Holdings, Inc. Profitability — ROE, Margins, and Quality Score
Medpace Holdings, Inc. (MEDP) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 89.8%, compared to the Industrials sector average of 8.9%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 20.9% versus the sector average of 3.3%.
On a margin basis, Medpace Holdings, Inc. reports gross margins of 30.8%, compared to 35.8% for the sector. The operating margin is 20.9% (sector: 6.2%). Net profit margin stands at 17.6%, versus 3.9% for the average Industrials stock. Revenue growth is running at 25.0% on a trailing basis, compared to 6.4% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
MEDP Debt, Balance Sheet, and Financial Health
Medpace Holdings, Inc. has a debt-to-equity ratio of 330.0%, compared to the Industrials sector average of 70.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.74x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $285M.
MEDP has a beta of 1.32, meaning it is more volatile than the broader market — a $10,000 investment in MEDP would be expected to move 32.3% more than the S&P 500 on any given day. The stability factor score for Medpace Holdings, Inc. is 44/100, reflecting average volatility within the normal range for its sector.
Medpace Holdings, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Medpace Holdings, Inc. reported revenue of $2.36B and earnings per share (EPS) of $15.64. Net income for the quarter was $412M. Gross margin was 30.8%. Operating income came in at $494M.
In FY 2025, Medpace Holdings, Inc. reported revenue of $2.53B and earnings per share (EPS) of $15.64. Net income for the quarter was $451M. Gross margin was 30.1%. Revenue grew 20.0% year-over-year compared to FY 2024. Operating income came in at $535M.
In Q3 2025, Medpace Holdings, Inc. reported revenue of $660M and earnings per share (EPS) of $3.95. Net income for the quarter was $111M. Gross margin was 29.8%. Revenue grew 23.7% year-over-year compared to Q3 2024. Operating income came in at $142M.
In Q2 2025, Medpace Holdings, Inc. reported revenue of $603M and earnings per share (EPS) of $3.16. Net income for the quarter was $90M. Gross margin was 29.8%. Revenue grew 14.2% year-over-year compared to Q2 2024. Operating income came in at $126M.
Over the past 8 quarters, Medpace Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $528M to $2.36B. Investors analyzing MEDP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MEDP Dividend Yield and Income Analysis
Medpace Holdings, Inc. (MEDP) does not currently pay a dividend. This is common among growth-oriented companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.
MEDP Momentum and Technical Analysis Profile
Medpace Holdings, Inc. (MEDP) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
MEDP vs Competitors — Industrials Sector Ranking and Peer Comparison
Within the Industrials sector, Medpace Holdings, Inc. (MEDP) ranks #125 out of 752 stocks based on the Blank Capital composite score. This places MEDP in the top quartile of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.
Comparing MEDP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MEDP vs S&P 500 (SPY) comparison to assess how Medpace Holdings, Inc. stacks up against the broader market across all factor dimensions.
MEDP Next Earnings Date
No upcoming earnings date has been announced for Medpace Holdings, Inc. (MEDP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MEDP? — Investment Thesis Summary
Medpace Holdings, Inc. presents a balanced picture with arguments on both sides.
In summary, Medpace Holdings, Inc. (MEDP) earns a Hold rating with a composite score of 44.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MEDP stock.
Related Resources for MEDP Investors
Explore more research and tools: MEDP vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MEDP head-to-head with peers: MEDP vs SOBO, MEDP vs TEN, MEDP vs GLDD.